Main clinical and laboratory features of the analyzed Ph-MPD patients
| . | PV . | ET . |
|---|---|---|
| No. of patients | 13 | 42 |
| Sex, male/female | 6/7 | 11/31 |
| Mean age, y | 69.3 ± 12.3 | 58.9 ± 17 |
| Median follow-up duration, y | 6.71 | 4.8 |
| Patients with no thrombosis | 6 | 30 |
| Patients with thrombotic complications | 7 | 12 |
| Thrombotic events arterial | 4 | 8 |
| Thrombotic events venous | 3 | 4 |
| Platelet count, ×109/L | 518 ± 220 | 746 ± 167 |
| HT ratio | 0.43 ± 0.05 | 0.40 ± 0.04 |
| WBC, ×109/L | 11 ± 4.5 | 8.8 ± 2 |
| Treatment adopted | ||
| Aspirin alone | 1 | 14 |
| Phlebotomies alone | 1 | 0 |
| HU alone | 3 | 2 |
| Warfarin alone | 0 | 4 |
| Aspirin and HU | 7 | 14 |
| Warfarin and HU | 1 | 1 |
| No therapy | 0 | 7 |
| . | PV . | ET . |
|---|---|---|
| No. of patients | 13 | 42 |
| Sex, male/female | 6/7 | 11/31 |
| Mean age, y | 69.3 ± 12.3 | 58.9 ± 17 |
| Median follow-up duration, y | 6.71 | 4.8 |
| Patients with no thrombosis | 6 | 30 |
| Patients with thrombotic complications | 7 | 12 |
| Thrombotic events arterial | 4 | 8 |
| Thrombotic events venous | 3 | 4 |
| Platelet count, ×109/L | 518 ± 220 | 746 ± 167 |
| HT ratio | 0.43 ± 0.05 | 0.40 ± 0.04 |
| WBC, ×109/L | 11 ± 4.5 | 8.8 ± 2 |
| Treatment adopted | ||
| Aspirin alone | 1 | 14 |
| Phlebotomies alone | 1 | 0 |
| HU alone | 3 | 2 |
| Warfarin alone | 0 | 4 |
| Aspirin and HU | 7 | 14 |
| Warfarin and HU | 1 | 1 |
| No therapy | 0 | 7 |
Blood counts refer to the time of the study.
Ph-MPD indicates Philadelphia-negative myeloproliferative disease; PV, polycythemia vera; ET, essential thrombocythemia; HT, hematocrit; and HU, hydroxyurea.